Comparison of differences between neoadjuvant chemotherapy and conventional chemotherapy for ovarian cancer in application, CA125 and prognosis

被引:0
作者
Zuo, Ying [1 ]
You, Dong [2 ]
Liu, Jianhui [2 ]
Ren, Ruizhen [3 ]
Li, Ling [4 ]
机构
[1] Qingdao Univ, Yantai Yuhuangding Hosp, Dept Gynaecol, Yantai, Shandong, Peoples R China
[2] Qingdao Univ, Yantai Yuhuangding Hosp, Dept Radiotherapy, Yantai, Shandong, Peoples R China
[3] Qingdao Univ, Yantai Yuhuangding Hosp, Dept Endocrinol, Yantai, Shandong, Peoples R China
[4] Linyi Canc Hosp, Dept Sci & Educ, 6 Cemetery East St, Linyi 276000, Shandong, Peoples R China
来源
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE | 2018年 / 11卷 / 05期
关键词
Neoadjuvant chemotherapy; conventional chemotherapy; ovarian cancer; prognosis; CA125; BREAST; PACLITAXEL; SURVIVAL; RISK;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective: To compare the application of neoadjuvant chemotherapy and conventional chemotherapy in the treatment of ovarian cancer and the changes of CA125 and the prognosis in patients after treatments. Methods: A retrospective analysis was made on 384 cases of ovarian cancer patients in the department of gynaecology and oncology in Yantai Yuhuangding Hospital Affiliated to Qingdao University from April 2008 to September 2013. Patients were randomized to the test group (192 patients with neoadjuvant chemotherapy) and the control group (192 patients receiving conventional chemotherapy) according to the way of treatments. The clinical efficacy in two groups of patients and the detection results of CA125 were compared, and all patients were followed up for a period of three years. Results: The response rate of the test group was 94.79%, which was prominently higher than that of the control group (77.09%, P<0.01). The incidence of adverse reactions in the test group was 16.15%, remarkably better than that in the control group (42.70%, P<0.01). There was no noted difference in bone marrow suppression between the two groups (18.23% and 23.96%, P=0.17) and no notable difference in serum concentration of CA125 between the two groups before chemotherapy was observed (P=0.541). The concentration of CA125 in the test group decreased markedly after three weeks and five weeks of chemotherapy, which was obviously lower than that in the control group (all P<0.01). The rates of survival at first, second and third years in the test group were 94.69%, 84.35%, 67.64%, respectively, while those in the control group were 81.43%, 66.05%, 49.60% respectively. Marked differences in the survival rates between the two groups were noted (P<0.05). Conclusion: Neoadjuvant chemotherapy can effectively improve the survival rate of ovarian cancer patients and reduce the incidence of different reactions during the treatment. Hence, it is worth generalization and application in clinical practice.
引用
收藏
页码:4991 / 4997
页数:7
相关论文
共 50 条
  • [1] Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer
    Alegria-Banos, Jorge A.
    Jimenez-Lopez, Jose C.
    Vergara-Castaneda, Arely
    Cantu de Leon, David F.
    Mohar-Betancourt, Alejandro
    Perez-Montiel, Delia
    Sanchez-Dominguez, Gisela
    Garcia-Villarejo, Mariana
    Olivares-Perez, Cesar
    Hernandez-Constantino, Angel
    Gonzalez-Santiago, Acitlalin
    Clara-Altamirano, Miguel
    Arela-Quispe, Liz
    Prada-Ortega, Diddier
    JOURNAL OF OVARIAN RESEARCH, 2021, 14 (01)
  • [2] Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer
    Jorge A. Alegría-Baños
    José C. Jiménez-López
    Arely Vergara-Castañeda
    David F. Cantú de León
    Alejandro Mohar-Betancourt
    Delia Pérez-Montiel
    Gisela Sánchez-Domínguez
    Mariana García-Villarejo
    César Olivares-Pérez
    Ángel Hernández-Constantino
    Acitlalin González-Santiago
    Miguel Clara-Altamirano
    Liz Arela-Quispe
    Diddier Prada-Ortega
    Journal of Ovarian Research, 14
  • [3] Serum CA 125 Level after Neoadjuvant Chemotherapy is Predictive of Prognosis and Debulking Surgery Outcomes in Advanced Epithelial Ovarian Cancer
    Matsuhashi, Tomohiko
    Takeshita, Toshiyuki
    Yamamoto, Akihito
    Kawase, Rieko
    Yamada, Takashi
    Kurose, Keisuke
    Doi, Daisuke
    Konnai, Katsuyuki
    Onose, Ryo
    Kato, Hisamori
    JOURNAL OF NIPPON MEDICAL SCHOOL, 2017, 84 (04) : 170 - 176
  • [4] Prognostic value of serial CA125 measurements during chemotherapy for patients with advanced ovarian cancer
    Koper, NP
    Massuger, LFAG
    Thomas, CMG
    Kiemeney, LALM
    Schijf, CPT
    Beex, LVAM
    Verbeek, ALM
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1997, 7 (02) : 127 - 133
  • [5] Dynamic Analysis of CA125 Decline During Neoadjuvant Chemotherapy in Patients with Epithelial Ovarian Cancer as a Predictor for Platinum Sensitivity
    Pelissier, Aurelie
    Bonneau, Claire
    Chereau, Elisabeth
    Rouge, Thibault De la Motte
    Fourchotte, Virginie
    Darai, Emile
    Rouzier, Roman
    ANTICANCER RESEARCH, 2016, 36 (04) : 1865 - 1871
  • [6] The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking
    Le, T.
    Hopkins, L.
    Faught, W.
    Fung-Kee-Fung, M.
    GYNECOLOGIC ONCOLOGY, 2007, 105 (03) : 712 - 715
  • [7] CA125 Level Association With Chemotherapy Toxicity and Functional Status in Older Women With Ovarian Cancer
    Won, Elizabeth
    Hurria, Arti
    Feng, Tao
    Mohile, Supriya
    Owusu, Cynthia
    Klepin, Heidi D.
    Gross, Cary P.
    Lichtman, Stuart M.
    Gajra, Ajeet
    Tew, William P.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (06) : 1022 - 1028
  • [8] CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy
    Pelissier, Aurelie
    Bonneau, Claire
    Chereau, Elisabeth
    Rouge, Thibault de la Motte
    Fourchotte, Virginie
    Dargi, Emile
    Rouzier, Roman
    GYNECOLOGIC ONCOLOGY, 2014, 135 (03) : 542 - 546
  • [9] Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer
    Kang, Sokbom
    Kim, Tae-Joong
    Seo, Sang-Soo
    Kim, Byoung-Gie
    Bae, Duk-Soo
    Park, Sang-Yoon
    GYNECOLOGIC ONCOLOGY, 2011, 120 (01) : 18 - 22
  • [10] Serum CA125 levels predict outcome of interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer
    Zhang, Dan
    Jiang, Yu-xia
    Luo, Shu-juan
    Zhou, Rong
    Jiang, Qing-xiu
    Linghu, Hua
    CLINICA CHIMICA ACTA, 2018, 484 : 32 - 35